Regeneration Biomedical presents early data showing stem cell treatment reduced levels of p-Tau and amyloid-beta in Alzheimer’s patients.
Last week, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, stem cell therapy company Regeneration Biomedical presented data from the first cohort of the Phase 1 clinical trial of its stem cell therapy for mild-to-moderate Alzheimer’s disease. The therapy aims to deliver the company’s proprietary adipose-derived stem cells (RB-ADSCs) directly to the brain, with the goal of kick-starting the repair and replacement of damaged neurons.
The small-scale FDA-cleared trial is designed to evaluate both the safety and initial efficacy of RB-ADSCs in nine patients with Alzheimer’s. Regeneration Biomedical’s CTAD presentation focused on the first three enrolled patients, who each received a single dose of RB-ADSCs delivered directly into the lateral ventricles of the brain using an “Ommaya reservoir” – a device implanted under the scalp to bypass the blood-brain barrier, a major obstacle in Alzheimer’s treatments.
Biomarker analysis at the 12-week mark demonstrated reductions in both p-Tau and amyloid-beta – two proteins strongly associated with Alzheimer’s disease progression. In cerebrospinal fluid (CSF) samples from the three patients, p-Tau levels decreased to “normal” levels, while amyloid PET scans also showed a reduction in amyloid buildup.
Regeneration Biomedical also reported its treatment produced signs of cognitive improvement, with two of the three patients showing increased Mini-Mental State Examination (MMSE) scores, a common measure of cognitive function.
The company’s founder Dr Christopher Duma, who presented the data at the conference, said that “improvements in Alzheimer’s disease biomarkers and an improving trend in a cognitive measure at up to 12 weeks are consistent with our hypothesis that infusion of Wnt-activated stem cells into the brain may initiate a cessation or reversal of at least some of the pathological processes underlying this devastating disease.”
According to Duma, the treatment also showed a tolerable safety profile with only minor adverse effects, including some discomfort from the liposuction required to collect adipose cells and mild incisional pain from the reservoir implantation. The injection process itself, lasting around eight minutes, required no anesthesia and caused no adverse effects.
The ongoing Phase 1 trial is an open-label, single-arm study that spans approximately one year, with each participant followed for up to 52 months to monitor longer-term safety and effects. Following the completion of its second dose cohort, the company is now enrolling its final cohort.
“The hope is that our cells will ‘turn on’ the stem cells that are sitting dormant in all of our brains, to initiate repair and replacement of damaged neurons,” Duma told us previously.
Photograph: Image-Source/Envato
Share this article:
EmailFacebookTwitterLinkedIn
Designs for Health launches Progenalen Pro Peptide for metabolic and aging support
October 28, 2025
Generation Lab secures $11 M seed round to scale SystemAge platform
October 27, 2025
Selah Center launches new integrative wellness sanctuary in San Diego
October 27, 2025
Halia Therapeutics’ ofirnoflast wins US orphan-drug designation for MDS
October 27, 2025
Genflow Biosciences publishes second European patent for SIRT6 variant in NASH
October 27, 2025
600and1 targets aging biology with new decoding and bioengineering plan
October 27, 2025
Nanoscope shows 3-year vision gains in study of MCO-010 for retinitis pigmentosa
October 24, 2025
Immortal Dragons backs Unlimited Bio in strategic longevity investment
October 24, 2025
Isaac Health partners with LillyDirect to broaden Alzheimer’s specialist care access
October 24, 2025
NRG Therapeutics recruits senior leadership to drive NRG5051 clinical launch
October 24, 2025
Telomir Pharmaceuticals unveils new data on Telomir-1 efficacy in cell models
October 24, 2025
Designs for Health launches CLB101 probiotic with ClostraBio partnership
October 24, 2025
L-Nutra rolls out Prolon® guided health program for weight and metabolic wellness
October 24, 2025
CND Life Sciences receives $3 million NIH grant for Parkinson’s risk study
October 23, 2025
TruDiagnostic links Ozempic ingredient to slower biological aging
October 23, 2025
Lifeist relaunches Mikra products on Amazon to boost U.S. access
October 23, 2025
Alector halts latozinemab programme after phase 3 fails key clinical endpoint
October 23, 2025
Designs for Health secures strategic investment from BDT & MSD Partners
October 22, 2025
More like this
Mission lands $13.3m to combat Parkinson’s via mitophagy
Biotech
Elevara lands $70m to combat chronic inflammation
Biotech
Derisking clinical trials requires a ‘human first’ approach
Biotech
Lilly invests in epigenetic reprogramming biotech
Biotech
Engineering serendipity in longevity
Biotech
Researchers call for ‘system-level’ approach to combat aging
Biotech
Pelage sweeps up $120m to reverse hair loss
Biotech
Transforming CNS drug discovery using ‘reactivated’ human brains
Biotech
New trial data supports Alzheimer’s drug candidate’s ‘disease-modyfing’ potential
Biotech
Is this mitochondria’s big moment?
Biotech
Longevity biotech activity ‘outpacing’ other segments
Biotech
Alzinova gets FDA Fast Track nod for Alzheimer’s vaccine
Biotech
AI-powered gene modulation startup lands $555m AstraZeneca deal
Biotech
Gene therapy startup targets ‘aging itself’ to combat blinding disease
Biotech
Klotho Neuro moves to acquire Turn Bio assets
Biotech
Aerska emerges from stealth to combat brain diseases with RNAi
Biotech
